Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Ashley Maier

Nurse Practitioner, Family Louisville, KY Nurse Practitioner

NPI 1790185254 CMS profile 10725347

3430 Newburg Rd Ste 250, Louisville, KY 40218

Open in the dashboard

General payments

$16,512

903 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ashley Maier of Louisville, KY is reported in the CMS Open Payments database as having received $16,512 across 903 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,640 198
2024 General $3,365 179
2023 General $3,571 187
2022 General $3,555 195
2021 General $2,380 144

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ashley Maier
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Ashley Maier were reported at $3,640. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Ashley Maier Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $2,380 $124 $35–$379 $132
2022 $3,555 $141 $44–$430 $149
2023 $3,571 $154 $49–$476 $160
2024 $3,365 $165 $51–$504 $164
2025 $3,640 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $2,806 148 payments
  2. Amgen Inc. $2,498 157 payments
  3. Janssen Biotech, Inc. $2,437 112 payments
  4. UCB, Inc. $1,734 108 payments
  5. Mallinckrodt Hospital Products Inc. $932 36 payments
  6. Novartis Pharmaceuticals Corporation $901 49 payments
  7. AstraZeneca Pharmaceuticals LP $736 35 payments
  8. E.R. Squibb & Sons, L.L.C. $712 50 payments
  9. Pfizer Inc. $580 36 payments
  10. Lilly USA, LLC $381 20 payments
  11. Other $2,796 152 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $16,208 899 payments
  2. Education $304 4 payments
Products named General payments · program years 2021–2025
  1. TREMFYA $2,217 102 payments
  2. RINVOQ $2,134 118 payments
  3. Cimzia $1,197 80 payments
  4. ACTHAR $932 36 payments
  5. Enbrel Inflammation $748 43 payments
  6. ORENCIA $712 50 payments
  7. Otezla $705 40 payments
  8. SAPHNELO $705 33 payments
  9. COSENTYX $589 28 payments
  10. Enbrel Inflammation $565 29 payments
  11. Other $7,993 458 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 28 drugs

Part D claims

1,356

Median for Nurse Practitioner: 389

Drug cost

$1,280,314

Median for Nurse Practitioner: $21,885

Branded share of claims

28.4%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Enbrel Sureclick Etanercept Brand 60 $486,357
Orencia Clickject Abatacept Brand 32 $191,339
Rinvoq Upadacitinib Brand 24 $162,219
Humira Adalimumab Brand 19 $128,970
Cosentyx Sensoready (2 Pens) Secukinumab Brand 13 $119,268
Enbrel Etanercept Brand 13 $92,678
Kevzara Sarilumab Brand 14 $61,385
Hydroxychloroquine Sulfate Generic 263 $9,428
Leflunomide Generic 109 $6,189
Methotrexate Methotrexate Sodium Brand 179 $5,921

The 10 drugs with the highest cost, of 28 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 21 billing codes

Paid by Medicare

$43,917

Medicare's payments for the services billed

Medicare patients

484

Average age 74

Services billed

1,122

340 women, 144 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Osteoporosis 28%
Ischemic heart disease 27%
Chronic kidney disease 21%
COPD 21%
Diabetes 20%
Depression 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 33 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RINVOQ
$364 24 —
TREMFYA
$345 — —
SKYRIZI
$226 — —
SAPHNELO
$209 — —
ORENCIA
$198 32 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 33 with Patron

Records

903 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record